1. PARP and Other DNA Damage Repair Inhibitors in Solid Tumors: An Update

2. Program Overview

3. Discussion Outline

4. DNA Repair

5. ABCs of DNA Repair

6. DNA Repair Defects in Cancer

7. DNA Repair Defects Can Be an Achilles' Heel

8. Synthetic Lethality and Cancer DNA Repair Defects

9. Increased Sensitivity of BRCA1-/- and BRCA2-/- Cells to PARP Inhibition

10. A Common Challenge for PARP Inhibitors: DNA Repair Pathway Complexity

11. Loss of Multiple DNA Repair Genes Can Sensitize to PARP Inhibition

12. Conclusions

13. PARP Inhibitors in the Treatment of Ovarian Cancer

14. The Homologous Recombination Pathway: Ideal Environment for PARP Inhibitors' Success

15. Study 19: PFS in All Patients and According to BRCA Status

16. NOVA: PFS in Patients With BRCA Mutations or Who Are HRD-Positive

17. SOLO2: Key Efficacy Outcomes

18. SOLO2: Key Efficacy Outcomes

19. ARIEL 3: Investigator-Assessed PFS

20. SOLO 2: AEs of Any Grade Reported in ≥10% of Patients in Either Arm

21. NOVA: TEAEs of Any Grade Reported in ≥10% of Patients in Either Arm

22. Single-Agent Therapy in BRCA-Mutated Ovarian Cancer: An Alternative?

23. Study 42: Olaparib Monotherapy in gBRCA-Mutated Ovarian Cancer

24. Study 10 and ARIEL 2: Rucaparib Monotherapy in gBRCA/sBRCA-Mutated Ovarian Cancer

25. Two Strategies for the Use of PARP Inhibitors in Advanced Ovarian Cancer

26. Where We Are Now: A Summary of Results With PARP Inhibitors

27. The Role of PARP Inhibitors in Breast Cancer Therapy

28. OLYMPIAD: PFS

29. OLYMPIAD: Summary of AEs, All Causality

30. OLYMPIAD: Additional Efficacy Data

31. OLYMPIAD: PFS in Relevant Subgroups

32. QoL in the OLYMPIAD Trial

33. Veliparib in a Randomized Phase 2 Study: BROCADE 2 - Grade 3/4 TEAEs

34. BROCADE 2: PFS

35. BROCADE 2: Tumor Response

36. Neoadjuvant Veliparib in Unselected TNBC: I-SPY2

37. ABRAZO Trial: Efficacy Results

38. ABRAZO: Hematologic Toxicities

39. Conclusions

40. Future Directions in Targeting DDR in Cancer: Conclusions

41. Discussion Overview

42. Multiple Malignancies Known to Associate With Homologous Recombination DDR

43. Clinical Response Rates by RECIST to Talazoparib 1 mg/day (Phase 2 Dose)

44. A Common Challenge for PARP Inhibitors: DNA Repair Pathway Complexity

45. Trial Design: A Chemical Screen in mCRPC Patients With Test and Validation Sets

46. Clinical Trial Results (TOPARP-A): Patient Characteristics

47. Primary Endpoint Analysis: Responses to Olaparib in Sporadic mCRPC

48. Germline Aberrations in DNA Repair in mCRPC

49. Antitumor Activity of Olaparib and Association With Defects in DNA Repair Genes

50. Multiple Combination Possibilities

51. Other DNA Repair Defects

52. Conclusions

53. Conclusions (cont)

54. Abbreviations

55. Abbreviations (cont)

56. Abbreviations (cont)

57. Abbreviations (cont)